Inside Precision Medicine Online Published: February 16, 2022 Read the Full Article >> Personalizing medicine using population-level insights can seem like a contradiction. On one hand, the goal is to better fit treatment to the individual patient, moving away from generalized approaches toward a “one size fits all” model. On the other, we have[…]
BioMed Central Online Published: 14 February 2022 Read the Full Manuscript >> Background Many second-generation antipsychotics (SGAs) are associated with weight gain and cardiometabolic effects. Antipsychotic-associated weight gain is linked to treatment interruptions, potentially increasing risk of relapse and hospitalization. This retrospective study assessed clinically significant weight gain (CSWG), treatment interruptions, and development of cardiometabolic[…]
OM1’s Dr. Richard Gliklich presents on leveraging the AAO-HFN Reg-ent Registry for research at the FDA-MDEpiNet conference “Cochlear Implant Innovation, Research and Advancement (CIRCA). View Agenda >>
Taylor & Francis Online Published: January 20, 2022 Read the Full Manuscript >> Objective To compare healthcare resource use (HCRU) in patients undergoing sinus surgery with or without steroid-eluting sinus implants. Methods A retrospective, observational cohort study using real-world evidence data (OM1, Inc, Boston, MA, USA) was conducted on adult patients with chronic rhinosinusitis (CRS)[…]
December 20, 2021 – Orphanet Journal of Rare Diseases Read the Full Article >> Background Fabry disease (FD) is a rare genetic disorder characterized by glycosphingolipid accumulation and progressive damage across multiple organ systems. Due to its heterogeneous presentation, the condition is likely significantly underdiagnosed. Several approaches, including provider education efforts and newborn screening, have[…]
